SureTrader Stock Hero Advertisement
Home > Boards > US OTC > Biotechs >

Amarantus BioScience Holdings, Inc. (AMBS)

AMBS RSS Feed
Add AMBS Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator joboggi, zoomboom, Rosym
Search This Board:
Last Post: 4/1/2015 11:56:55 AM - Followers: 721 - Board type: Free - Posts Today: 36



Amarantus BioScience Holdings, Inc.

   Amarantus is a biotechnology company developing treatments and diagnostics for diseases associated with neurodegeneration and protein misfolding-related apoptosis.
   The company has licensed Eltoprazine, a Phase 2B ready Parkinsons Levadopa induced Dyskinesia.
   The company has an exclusive worldwide license to the Lymphocyte Proliferation test ("LymPro Test®") for Alzheimer's Disease and owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders.
   Amarantus is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders.
   The Company also owns intellectual property rights for the diagnosis of Parkinson's Disease ("NuroPro") and the discovery of neurotrophic facotrs ("PhenoGuard").

ESS, previously known as PermaDerm®  is being developed to be the only tissue-engineered skin prepared from autologous (patient's own) skin cells consisting of both epidermal and dermal layers. A small harvested section of the patient's own skin can be grown to graft an area one hundred times its size in as little as thirty days. 

MSPrecise is a groundbreaking advancement for the diagnosis of multiple sclerosis and is anticipated to play a pivotal role given the current high rate of misdiagnosis
MSPrecise is a lab-developed test, and the successful completion of the validation study paves the way for this clinically important test to be commercialized in 2015. 
 For further information, please visit www.Amarantus.comor connect with the company in FacebookTwitter, LinkedIn & Google+





 
 
PRESS RELEASES & NEWS ARTICLES

Amarantus BioScience Opens Investigational New Drug (IND) Application With the U.S. Food and Drug Administration Allowing the Start of a Phase 2b Program of Eltoprazine in Parkinson's Disease Levodopa-Induced Dyskinesia
March 26, 2015
Amarantus Shareholder Update: Fundamental Progress on the Pipeline and Strategy Continues
Thursday, March 26th, 2015 
Amarantus to Present at the Neurotech Investing and Partnering Conference on Tuesday, April 7, 2015

March 23, 2015
A Deep Look At Amarantus’ Phase 2b Eltoprazine For Parkinson’s Dyskinesia
By Jason NapodanoWednesday, March 4, 2015
Large Pharmaceuticals and Biotech Startups Partnering To Develop Alzheimer’s Treatments
February 26, 2015
Amarantus to Present Positive Alzheimer's Disease Biomarker Data on the LymPro Test(R) at the 12th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
Feb. 23, 2015
Amarantus Announces First Alzheimer's Biomarker Services Collaboration for LymPro Test(R) With Anavex Life Sciences Corp.
Feb. 18, 2015
New therapeutic principle for Parkinsonian dyskinesia shows clinical effect
Feb. 10, 2015
Amarantus Announces Publication in BRAIN of Eltoprazine Phase 2a Clinical Study for Treating Parkinson's Disease Levodopa-Induced Dyskinesia - The study was partially supported by a grant from Michael J. Fox Foundation for Parkinson's Research.
Feb. 10, 2015
Amarantus Creates Alzheimer`s Disease Diagnostics Scientific Advisory Board
 FEBRUARY 3RD, 2015
Congressman Fattah Meets with Biotech Company on Brain Research Efforts; Announced as Co-Chair of Alzheimer`s Caucus
February 03/15
Amarantus Announces Exclusive Option Agreement With Georgetown University to License Patent Rights for Blood Based Biomarkers for Alzheimer's Disease
Jan. 15, 2015

Developing an Accurate Test for Multiple Sclerosis

 Mar 5, 2014

 

December 12, 2014
SNNLive - Amarantus BioScience Holdings, Inc.

 

Oct. 19, 2014
Amarantus BioSciences






 
 
 
    
       

 

Company Information

Investor Relations

Transfer Agent

Amarantus BioScience Holdings, Inc.
c/o Janssen Labs @ QB3
953 Indiana Street
San Francisco, CA 94107

c/o ICS Corporate Services SA
29 quai du Mont Blanc
CH-1201 Geneva
Switzerland

info@amarantus.com
pr@amarantus.com


Phone: (408) 737-2734
Fax: (408) 852-4427

Aimee Boutcher
Director of Investor Relations
Amarantus BioScience Holdings, Inc
.

408-737-2734 x101
ir@amarantus.com


Gerald's email address

Gerald@amarantus.com







 
VStock Transfer, LLC
77 Spruce Street, Suite 201
Cedarhurst, NY 11516

Attn: Allison Niccols


Phone: 212-828-8436
Toll-Free: 855-9VSTOCK
Fax: 646-536-3179

info@vstocktransfer.com

www.VStockTransfer.com 


 
 
  Amarantus Receives Orphan Drug Designation for MANF From U.S. Food and Drug Administration for Treatment of Retinitis Pigmentosa
 "We are very pleased to receive orphan drug designation for MANF in RP. This represents an important milestone for the company as well as a significant step forward for our clinical and regulatory strategy," said Gerald E. Commissiong
 Most people with RP are legally blind by age 40. It is estimated that the market opportunity for Retinitis Pigmentosa exceeds $10B annually.

 
“I believe in MANF,” said Dr. Rubinfeld, “I have reviewed a great number of technologies in my 45 year career in the biopharmaceutical field, and I believe that MANF could be one of the biggest successes that I have ever seen  cool
 
 
smiley   Gerald E. Commissiong  -  We recognize that it is not optimal to up list from a position of weakness, and therefore we will only consider an up list from a position of strength while the Company is making good progress in the market. We believe the milestones we’ve outlined above and will put us in that position. However, if we do not believe we have achieved sufficient shareholder value creation, we will consider delaying the up list until such time as the market recognizes our true value.
 
 
Gerald E. Commissiong, President & CEO, will be presenting at the Neurotech Investing and Partnering Conference being held April 7-8, 2015 at the Hotel Nikko in San Francisco, CA. Mr. Commissiong will discuss the Company's proprietary Alzheimer's blood diagnostic LymPro Test®and the strategic plans for Amarantus Diagnostics on Tuesday, April 7, 2015, from 10:30-11:30 a.m. Pacific Daylight
                                                                                    
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AMBS
Current Price
Volume:
Bid Ask Day's Range
Wiki
AMBS News: Current Report Filing (8-k) 03/31/2015 05:29:50 PM
AMBS News: Notification That Annual Report Will Be Submitted Late (nt 10-k) 03/31/2015 04:46:53 PM
AMBS News: Amarantus BioScience Opens Investigational New Drug (IND) Application With the U.S. Food and Drug Administration Allowing the... 03/26/2015 10:00:00 AM
AMBS News: Amended Current Report Filing (8-k/a) 03/25/2015 06:02:42 AM
AMBS News: Amarantus to Present at the Neurotech Investing and Partnering Conference on Tuesday, April 7, 2015 03/23/2015 08:05:00 AM
News News Alert: Current Report Filing (8-k) 03/31/2015 05:29:50 PM
PostSubject
#110746  Sticky Note Jason Napodano - 15 Biotech Names For 2015 Rosym 01/05/15 04:13:55 PM
#104968  Sticky Note MJFF is firm with their notion that NFs joboggi 07/17/14 02:01:07 AM
#112403   Right, like before. Later proven untrue. After TDA dshade 04/01/15 11:56:55 AM
#112402   http://www.otcmarkets.com/stock/ambs/short-sales Yep there is essentially no joboggi 04/01/15 11:45:09 AM
#112401   no one is going to buy Lympro in joboggi 04/01/15 11:17:42 AM
#112400   aha, and why would you do that? There joboggi 04/01/15 11:15:15 AM
#112399   Ron. That us on .045. Nice dshade 04/01/15 11:01:38 AM
#112397   Coinciding with babble like days when TDA had dshade 04/01/15 11:00:27 AM
#112396   Gerald has bought a portfolio of worthless assets Alapis 04/01/15 10:57:17 AM
#112395   Your obsession w Gerald is interesting. Portfolio has dshade 04/01/15 10:55:51 AM
#112394   blablabla....how can someone still believe this Gerald BS Alapis 04/01/15 10:50:51 AM
#112393   no this is different...these shares are from financing Alapis 04/01/15 10:49:54 AM
#112392   Fear mongering. AMBS is building and diversifying portfolio. dshade 04/01/15 10:49:16 AM
#112390   To me that's just another form of dilution...paying lighter than AIR 04/01/15 10:47:21 AM
#112389   it is NOT dilution as everybody thinks....it is Alapis 04/01/15 10:45:16 AM
#112388   well i guess you are in the same Alapis 04/01/15 10:43:34 AM
#112387   WHERE IS THIS COMING FROM? This kind of huge lighter than AIR 04/01/15 10:43:27 AM
#112386   Nonsense. Next. Been here since .007 and know dshade 04/01/15 10:41:35 AM
#112385   stop this short theorie...there is ZERO short position Alapis 04/01/15 10:36:29 AM
#112384   Shorts don't care about the progress on portfolio dshade 04/01/15 10:35:03 AM
#112383   no please be honest here: Gerald is promoting Alapis 04/01/15 10:30:52 AM
#112382   Still places valuation much higher than .045 dshade 04/01/15 10:28:58 AM
#112381   Opportunity on misplaced fear? dshade 04/01/15 10:28:11 AM
#112380   I loaded again my boat..... GO AMBS ron51 04/01/15 10:28:09 AM
#112379   you mean BILLION SHARES! LOL Gerald and his Alapis 04/01/15 10:27:45 AM
#112378   What's happening huge volume.... and minus 9% ron51 04/01/15 10:21:47 AM
#112377   ACTUALLY the potential is $billions in portfolio. Time dshade 04/01/15 10:16:16 AM
#112376   Fancy to see you here georgie. I jjr04001 04/01/15 10:00:46 AM
#112375  Restored To all fellow shareholders: WE MUST GET RID Alapis 04/01/15 09:50:44 AM
#112374   TOXIC Financer DOMINION adds nearly 5% to ownership. Sgt. Pepper 04/01/15 09:30:40 AM
#112373   TOXIC FINANCER Dominion is the LARGEST shareholder Sgt. Pepper 04/01/15 09:30:28 AM
#112372   150,000,000 Share DILUTION Coming Sgt. Pepper 04/01/15 09:30:17 AM
#112370   Gerald tweeted last night jeffshir 04/01/15 08:58:51 AM
#112369   to answer Gerwolds question, all of those assets JPetroInc 04/01/15 08:18:22 AM
#112368   $AMBS chart - BULLISH INVERTED HAMMER reversal pattern ospreyeye 04/01/15 01:59:50 AM
#112367   [pre]Daniel Pinsky ?@pinsky6 Mar 30 Rosym 03/31/15 08:46:41 PM
#112366   Normal. No big deal. Relax. dshade 03/31/15 07:39:36 PM
#112365   "we're significantly undervalued" JPetroInc 03/31/15 07:25:23 PM
#112364   You are correct, this is ridiculous. How Deputy123 03/31/15 06:22:21 PM
#112363   If you think the CFO has no involvement brharris 03/31/15 06:16:45 PM
#112359   When was the last time AMBS filed a dsw 03/31/15 05:04:40 PM
#112358   You got the NT. Not surprising with all brharris 03/31/15 05:02:57 PM
#112357   10K - Late Filing JPetroInc 03/31/15 05:02:19 PM
#112356   Manipulation, vulgars who are doing a dirty job! sante1 03/31/15 04:41:11 PM
#112355   The ol' Deputy was right again. Deputy123 03/31/15 04:23:41 PM
#112354   Textbook morning star. Bullish. jjr04001 03/31/15 04:05:38 PM
#112353   Ugh - the sad irony of it all... JPetroInc 03/31/15 03:36:04 PM
#112352   Bogus VNDM block attempt. dshade 03/31/15 02:09:12 PM
#112351   maybe RGIN sold their restricted shares becuase they Alapis 03/31/15 12:01:01 PM
#112348   at least we have more buy volume than Alapis 03/31/15 11:43:38 AM
#112347   well zzom congrats ...you are now moderator of Alapis 03/31/15 11:35:42 AM
#112343   if they file for a NT they are Alapis 03/31/15 09:48:25 AM
PostSubject